- MCA filings & documents
- P&L, balance sheet, cash flow & ratios
- Year-wise charts & analysis
- One credit = one full company report
- Use across any company, anytime
- Credits valid for 12 months
Key Metrics
Company Health Scores
Health scores for Medzone Pharmaceuticals covering vendor trust, statutory compliance, financial health and director risk - derived from MCA filings, GST and EPFO records, financial statements and the company's board history.
About Medzone Pharmaceuticals
Medzone Pharmaceuticals is an MCA-registered Indian company: a Private Limited Indian Non-Government Company (CIN U24232PY2010PTC002426). Business overview includes Pharma (Pharmaceutical Retailers & Distributors), incorporated on March 11, 2010 (16+ years old), headquartered in Pondicherry, Pondicherry, India. The company is currently Active with Active Non-Compliant compliance status. For FY 2024, the company reported revenue of ₹81.23 Lakh with a loss of ₹25.65 Lakh. It has 5 active directors. The company employs approximately 9 people.
- Location No.6, Pipdic Main Road Thirubuvanai, Mannadipet Commune, Pondicherry, Pondicherry - 605107
- Website medzonepharma.com
Financial Performance of Medzone Pharmaceuticals
| Metrics | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 2,20,083.04 cr | 2,35,431.21 cr | 2,51,890.00 cr | 2,18,400.00 cr | 1,95,200.00 cr | 1,72,000.00 cr | 1,59,000.00 cr |
| Profit/Loss | 13,969.70 cr | 4,810.00 cr | 12,200.00 cr | 9,100.00 cr | -8,200.00 cr | 3,200.00 cr | 5,100.00 cr |
| Cash & Bank Balance | 38,200.00 cr | 35,100.00 cr | 32,000.00 cr | 28,500.00 cr | 25,200.00 cr | 22,000.00 cr | 19,800.00 cr |
| Net Worth | 1,26,731.94 cr | 1,37,500.00 cr | 1,40,200.00 cr | 1,28,000.00 cr | 1,15,000.00 cr | 1,02,000.00 cr | 95,000.00 cr |
| EBITDA | 27,865.49 cr | 29,800.00 cr | 30,200.00 cr | 27,000.00 cr | 24,500.00 cr | 22,000.00 cr | 20,100.00 cr |
Financial Ratios
Values in Crores (Cr) - illustrative trend
| Ratio | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Net Profit Margin | 10.54 | 3.20 | 2.10 | 1.80 | 0.50 |
| Debt to EBITDA | 2.14 | 1.90 | 1.70 | 1.50 | 1.20 |
| Interest Coverage Ratio | 0.47 | 0.50 | 0.45 | 0.40 | 0.35 |
| Debt to Equity | 0.88 | 0.90 | 0.85 | 0.80 | 0.75 |
| Return on Equity | 12.10 | 3.00 | 2.00 | 1.50 | 0.20 |
| Current Ratio | 1.20 | 1.15 | 1.10 | 1.05 | 0.99 |
| Quick Ratio | 0.95 | 0.92 | 0.88 | 0.85 | 0.80 |
| EBITDA Margin | 12.00 | 10.00 | 8.00 | 7.00 | 5.00 |
| Return on Capital Employed | 8.00 | 2.00 | 1.00 | 0.20 | 0.00 |
| Earning Per Share | 4.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EPFO Establishments (1)
Current Directors of Medzone Pharmaceuticals (5)
Charges of Medzone Pharmaceuticals
| Lender | Amount | Status |
|---|---|---|
|
Indian Overseas Bank
Creation Date: 18 Mar 2022
|
7.80 Lakh | Open |
|
Indian Overseas Bank
Creation Date: 11 Mar 2011
|
50.00 Lakh | Open |
Business Activity
| Activity Group | Description | Turnover % |
|---|---|---|
| Manufacturing | - | 100.00 |
Flagged By Authority
Regulatory and exchange flags (preview)
Legal Cases of Medzone Pharmaceuticals
- Abdul Malick Shamshudeen
- Deivasigamani Alexander Jesudasan
- Dayalan Nadesan
- Rathina Kumar Balasubramanian
- Chandra Gnanatilakan
Disclaimer: Data on this page is compiled from public sources as available in our system at the time of the last update and is for general information only. Scores are derived indicators, not credit ratings or advice - please verify from official sources and consult a professional before making any business or financial decision.